Tagged with ART

Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…

Health This chart shows the varying levels of health literacy in Europe. Health literacy is a serious issue in Hungary where 19% of the population have ‘inadequate’ knowledge and 33% are rated as ‘problematic.’ Click here to read more articles and interviews from Hungary

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…

Novartis Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries.   The opportunities offered by big data are present and we need to tap into this immense potential Heidrun Irschik, Novartis Big data: a technological phenomenon with potential commensurate to…

Pharma The below chart shows the sources of funding for R&D investment in Italy, with only 7% of total investment originating from pharmaceutical and health-oriented biotech. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Italy Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of liquidity in the market, including amongst the family businesses … and there are now a lot of companies looking for…

Health The chart below illustrates the potential for a shift in healthcare provision towards home care in France; a country with a rapidly increasing over 60 population, an expensive nursing home system, and a culture of living at home into old age. Click here to download the latest free pharma report on…

Pharma France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a tradition of openness and understanding of dermatology. [France is] a unique environment for the growth of dermo-cosmetic brands. French dermatologists have a…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma The following chart shows the number of clinical trials in Italy per year. Peaking in 2008 and slumping slightly shortly after, the numbers have returned to robust levels with 550+ trials in total in 2013 and 250+ important Phase I and II trials. Click here to read more articles and…

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…